UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) June 7, 2004
------------
CollaGenex Pharmaceuticals, Inc.
--------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-28308 52-1758016
- --------------------------------------------------------------------------------
(State or Other (Commission File Number) (IRS Employer
Jurisdiction Identification No.)
of Incorporation)
41 University Drive, Newtown, Pennsylvania 18940
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip
Code)
(215) 579-7388
---------------------------------
(Registrant's telephone number,
including area code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
- ---------------------
On June 7, 2004, CollaGenex Pharmaceuticals, Inc., a Delaware corporation,
entered into a Fourth Loan Modification Agreement with Silicon Valley Bank with
respect to the Loan and Security Agreement dated March 19, 2001, as previously
amended, between the parties. Such Fourth Loan Modification Agreement further
amends the Loan and Security Agreement to, among other things, extend the
Maturity Date, as defined therein, to May 31, 2006 and to increase the Maximum
Credit Limit, as defined therein, to $5,000,000.
The foregoing statements are qualified in their entirety by the above
referenced Fourth Loan Modification Agreement, which is filed herewith as
Exhibit 10.1 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
- ---------------------------------------------------------------------------
(c) Exhibits.
Exhibit No. Description
----------- -----------
10.1 Fourth Loan Modification Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
COLLAGENEX PHARMACEUTICALS, INC.
By: /s/Colin W. Stewart
-----------------------------
Colin W. Stewart
President and Chief Executive Officer
(Principal Executive Officer)
Date: June 7, 2004